다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Elevation Oncology Inc (ELEV)
Elevation Oncology Inc (ELEV) 뉴스

ELEV

Elevation Oncology (ELEV)

Elevation Oncology Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ELEV

1 2 3 4 5 6 7 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/03/07	07:12	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ELEV	Elevation Oncology Inc
2025/03/07	06:52	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELEV	Elevation Oncology Inc
2025/03/07	06:30	PR Newswire (US)	Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements	NASDAQ:ELEV	Elevation Oncology Inc
2025/02/25	21:30	PR Newswire (US)	Elevation Oncology to Participate in Upcoming Investor Conferences	NASDAQ:ELEV	Elevation Oncology Inc
2025/02/20	06:25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ELEV	Elevation Oncology Inc
2025/02/20	06:20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ELEV	Elevation Oncology Inc
2025/02/20	06:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ELEV	Elevation Oncology Inc
2025/02/15	03:34	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ELEV	Elevation Oncology Inc
2025/02/01	06:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELEV	Elevation Oncology Inc
2025/01/13	21:45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELEV	Elevation Oncology Inc
2025/01/13	21:30	PR Newswire (US)	Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones	NASDAQ:ELEV	Elevation Oncology Inc
2024/12/12	21:30	PR Newswire (US)	Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors	NASDAQ:ELEV	Elevation Oncology Inc
2024/12/05	21:30	PR Newswire (US)	Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024	NASDAQ:ELEV	Elevation Oncology Inc
2024/11/26	21:30	PR Newswire (US)	Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference	NASDAQ:ELEV	Elevation Oncology Inc
2024/11/20	06:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ELEV	Elevation Oncology Inc
2024/11/15	09:05	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ELEV	Elevation Oncology Inc
2024/11/06	21:45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELEV	Elevation Oncology Inc
2024/11/06	21:30	PR Newswire (US)	Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements	NASDAQ:ELEV	Elevation Oncology Inc
2024/11/06	21:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ELEV	Elevation Oncology Inc
2024/09/23	20:30	PR Newswire (US)	Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2	NASDAQ:ELEV	Elevation Oncology Inc
2024/09/21	05:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELEV	Elevation Oncology Inc
2024/09/03	20:30	PR Newswire (US)	Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference	NASDAQ:ELEV	Elevation Oncology Inc
2024/08/20	05:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ELEV	Elevation Oncology Inc
2024/08/06	20:45	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ELEV	Elevation Oncology Inc
2024/08/06	20:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELEV	Elevation Oncology Inc
2024/08/06	20:10	PR Newswire (US)	Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements	NASDAQ:ELEV	Elevation Oncology Inc
2024/08/06	20:00	PR Newswire (US)	Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2	NASDAQ:ELEV	Elevation Oncology Inc
2024/07/16	02:17	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ELEV	Elevation Oncology Inc
2024/06/27	20:30	PR Newswire (US)	Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer	NASDAQ:ELEV	Elevation Oncology Inc
2024/06/18	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ELEV	Elevation Oncology Inc

검색 관련기사 보기:NASDAQ:ELEV

1 2 3 4 5 6 7 다음 >>

US Dollar vs Sterling

American Express

Gold vs US Dollar

BNP Paribas (QX)

JP Morgan Chase

Health Care Select Sector

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관